glp-1 pipeline The GLP-1R plus strategy for curbing the obesity epidemic What's next for GLP-1 innovation:

Can I stop immediately

Chronic intestinal pseudo-obstruction: manifestations, natural history and management

Yin TT, et al

Semaglutide at maximum dose produces an intervention magnitude of approximately 1,300 kcal per day, with an expected plateau timeline of around 24 months

Initially developed for type 2 diabetes, these therapies are now being explored for obesity, cardiovascular disease, and neurological conditions

For the evaluation of the effects of treatments on insulin sensitivity, insulin tolerance tests (ITT) were conducted 5 days after implementation of the GTTs, which allowed the proper recovery and washout of the animals